Flamel Technologies’ drug delivery platforms are widely endorsed by the Industry:
| Company | Product / Description | Indications | Technology | Status |
|---|---|---|---|---|
 |
Coreg CR (controlled release carvedilol phosphate) |
Cardiovascular diseases | Micropump | Marketed in the USA |
 |
NHP-554 (Micropump aspirin) |
Cardiovascular diseases | Micropump | Approved in EU, US NDA filing expected in 2012* |
 |
IFN-β XL (interferon beta-1a) |
Multiple sclerosis | Medusa | Phase 1 |
 |
Undisclosed | |||
 |
THA-902 | Pain | Medusa | Development stage |
 |
Controlled release formulations of multiple products, incl. TGF-beta1 inhibitors P144 (Disitertide) and P17, and MTA (methylthioadenosine) | Multiple | Medusa or Micropump | Development stage |
 |
Medusa-based hydrogel depot formulation of the small molecule antibiotic, tigecycline | Multiple | Medusa | Development stage |
| Undisclosed | Pain molecules | Misuse of scheduled drugs |
Trigger Lock | Undisclosed (see press release April 28, 2011) |
| In addition, Flamel has several other undisclosed partnerships with leading pharmaceutical and biotechnology companies. | ||||
* New Haven Pharmaceuticals’ website